



A New Spin on Nasal Drug Delivery

Corporate Overview

19805 North Creek Parkway
Bothell, WA 98011
Telephone: 425-640-9249
Fax: 425-673-5783

Established: 2001
Employees: 9
Ownership: Private
www.kurvetech.com

Introduction

Kurve Technology, Inc. designs and develops nasal drug delivery systems. While most nasal drug delivery companies concentrate on chemically reformulating existing formulations, Kurve Technology focuses on improving an essential, yet underdeveloped link in the nasal delivery chain - *the drug delivery device*. Kurve Technology's business model targets partnerships with pharmaceutical companies, offering a co-branded device for nasal delivery of topical, systemic, and nose-to-brain formulations.

Market Overview

The global market for drug-device combinations is expected to increase at an average annual growth rate of 13.6% and reach \$11.5B in 2010, compared with \$5.4B in 2004 according to *Business Communications Co. Inc.* The intranasal drug delivery market is forecasted at \$2.1B in 2007 growing to over \$4 billion in 2012 according to *Frost & Sullivan Healthcare Group*. Osteoporosis is expected to have the largest revenue gain in the intranasal drug delivery market, increasing to 18.2% of the market by 2012.

In addition to topical and systemic delivery applications, the pharmaceutical industry is researching intranasal delivery for the administration of nose-to-brain drug therapies for the treatment of central nervous system (CNS) diseases such as Alzheimer's and Parkinson's. Given the wide range of nasal drug delivery applications from chronic rhinosinusitis to pain management, the market for Kurve Technology's products is over 200 million patients worldwide.

Controlled Particle Dispersion® Technology

Using the principal of vortical flow, Kurve Technology's patent-pending Controlled Particle Dispersion (CPD)® technology effectively disrupts inherent nasal cavity airflows to saturate the entire nasal cavity. CPD optimizes droplet size, velocity and trajectory to lengthen compound residence time and minimize peripheral deposition to the lungs and stomach.

Other nasal delivery methods, such as spray pumps and nebulizers, do not adequately alter existing airflow patterns. In fact, in most cases, up to 90% of formulations simply fail to reach their intended target.

The CPD technology platform is extremely flexible, capable of delivering a wide range of topical, systemic, and nose-to-brain therapies, including solutions and suspensions, with droplet sizes and aerodynamics customized to drug requirements.

ViaNase™ & ViaNase ID™ Atomizers

ViaNase is a pocket-sized advanced electronic atomizer incorporating CPD. ViaNase ID add intelligent delivery features with programmable active electronics enabling dose counting, abuse and counterfeit lock-outs, and web-based data downloads.



Management

Marc Giroux Chairman/CEO Kurve Technology's Lead Inventor and Founder

Marc was most recently the President of EES, Inc. - a high tech staffing company placing executives across the USA. EES' main focus was consulting and building executive teams from early stage through exit strategy. Marc is considered an industry expert on the formation and building of teams. Earlier in his career, Marc spent 13 years in high-tech manufacturing where he developed and invented new products and designed efficiency equipment for production manufacturing. A long-time sinusitis and allergy sufferer, Marc invented the proprietary Kurve technology. He leads Kurve's business development efforts with investors and partners and guides the engineering team.

William DeGroot President/COO

Bill has 30 years experience in the medical device and pharmaceutical industry. His roles include President of Surgical Specialties Corporation in Reading, PA, and Vice President-International for American Home Products in St. Louis, MO, where he formed the international sales group and grew it into a \$100 million division. He was also the VP of Operations for SpaceLabs Medical, a \$300 million medical manufacturer. He was most recently the COO of MeDoctor - a medical diagnosis software company.

Michael Rackley - VP Business Development

Michael has extensive experience within the pharmaceutical and biotech industries. Before joining Kurve, he founded Titan Technology Consulting, Inc. where he conducted sales force development and product commercialization consulting that resulted in the licensing of pharmaceutical products for several mid-sized firms. Previously, Michael led efforts at LiFizz/EffRx, Inc. that transformed the company into a viable pharmaceutical entity by raising \$1.6 million in capital and authoring key patent protection. Michael also held roles at Bristol Myers Squibb and AH Robins. He holds a BS in Business Administration from West Virginia University.

Robert Kamp – VP Corporate Development

Robert brings 20 years of Business and Corporate Development experience to Kurve. He has extensive in and out-licensing experience in the high technology and petro-chemical industries. Most recently he was the President of RWK Technologies where he provided technology clients with business development services for international and domestic licensing, as well as capital raising and corporate development consulting services. Robert possesses a BS in Engineering from Iowa State University.

Clinical Advisory Board

Rick Johnson, MD Partner at Allergy and Asthma Associates and Clinical Professor, UW Medical School

Calvin H. Knapp, Jr., MD Seattle Head, Neck and Plastic Surgery

John D. Burgoyne, Jr., MD Seattle Head, Neck and Plastic Surgery

Robert Bettis, MD Edmonds Family Medicine Clinic

Contact Information

For more information, please call 425-640-9249 or visit www.kurvevtech.com. Media inquiries should be directed to Christine Slocumb at cslocumb@kurvetech.com.